Steven T Gill returns to Alimera as VP, Thought Leader Engagement
pharmafile | April 3, 2020 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Alimera Sciences, Novartis, pharma
Ophthalmology specialist Alimera Sciences has announced that Steven T Gill is to return to the company in the newly created role of Vice President, Thought Leader Engagement.
Gill had previously served at Alimera as its Senior Director, Thought Leader Liaison, before leaving the company for Novartis, where he most recently held the position of Associate Director, Thought Leader Liaison at Novartis US.
Gill has amassed over 20 years in the medical profession with 16 of those specifically in the retinal field. In the past, he has served as a Medical Science Liaison at Ophthotech and as Regional Sales Director and later Medical Science Liaison at Eyetech Pharmaceuticals.
In his new role, Gill will liaise with physicians and professional societies to advocate on behalf of Alimera, alongside leading a team in driving customer access through long-term partnerships with these key allies.
“We are extremely pleased to welcome Steve back to Alimera in this new role intended to elevate our advocacy among key opinion leaders and drive increased peer-to-peer engagement between customers currently using Iluvien and those exploring its use in their practices,” commented Rick Eiswirth, Alimera’s President and Chief Executive Officer. “Steve joins us at a time when the need to reduce the recurrence of retinal disease and provide better vision with fewer visits to the physician’s office for treatment potentially becomes more evident.”
Gill himself added: “I am honoured and excited to rejoin Alimera and work with their dedicated team that is committed to the retina community, and the patients they serve. I look forward to working across Alimera’s entire commercial organisation to increase customer awareness and understanding of Iluvien and to improve the lives of patients diagnosed with diabetic macular edema.”
Related Content
Pharma sees climate disruption as growing supply-chain risk
Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …
AI in pharma: From lab development to patient impact
In the decade to 2025, AI use in vaccine development has increased markedly but is …
Scotland starts newborn screening for SMA
As part of a two-year evaluation funded by the Scottish government and Novartis, Scotland will …
